Fig. 3

In vivo anti-tumor activity of ZnONP nanocomposites on EAC-challenged mice. EAC-challenged mice IP inoculated with PBS, DOX (0.4 mg), ZnONPs (0.5 mg), ZnONPs/DOX (0.7 mg), ZnONPs/FA (0.5 mg) or ZnONPs /DOX/FA (0.8 mg). Mice were sacrificed on day 11 post tumor challenge and Ascitic EAC tumor cells were harvested to determine their viability using trypan blue viability test. Data were represented as mean ± SD (n = 10). Difference between groups was considered statistically significant at P < 0.05. Note: ^a,b Statistically significant difference as compared to the corresponding means of the EAC group (a), the DOX group (b) within each column